Merck Manual

Please confirm that you are a health care professional


Gastroesophageal Reflux Disease (GERD)


Kristle Lee Lynch

, MD, Perelman School of Medicine at The University of Pennsylvania

Last full review/revision Jul 2019| Content last modified Jul 2019
Click here for Patient Education
NOTE: This is the Professional Version. CONSUMERS: Click here for the Consumer Version
Topic Resources

Incompetence of the lower esophageal sphincter allows reflux of gastric contents into the esophagus, causing burning pain. Prolonged reflux may lead to esophagitis, stricture, and rarely metaplasia or cancer. Diagnosis is clinical, sometimes with endoscopy, with or without acid testing. Treatment involves lifestyle modification, acid suppression using proton pump inhibitors, and sometimes surgical repair.

Gastroesophageal reflux disease (GERD) is common, occurring in 10 to 20% of adults. It also occurs frequently in infants, typically beginning at birth (see Gastroesophageal Reflux in Infants).


The presence of reflux implies lower esophageal sphincter (LES) incompetence, which may result from a generalized loss of intrinsic sphincter tone or from recurrent inappropriate transient relaxations (ie, unrelated to swallowing). Transient LES relaxations are triggered by gastric distention or subthreshold pharyngeal stimulation.

Factors that contribute to the competence of the gastroesophageal junction include the angle of the cardioesophageal junction, the action of the diaphragm, and gravity (ie, an upright position). Factors that may contribute to reflux include weight gain, fatty foods, caffeinated or carbonated beverages, alcohol, tobacco smoking, and drugs. Drugs that lower LES pressure include anticholinergics, antihistamines, tricyclic antidepressants, calcium channel blockers, progesterone, and nitrates.


GERD may lead to esophagitis, peptic esophageal ulcer, esophageal stricture, Barrett esophagus, and esophageal adenocarcinoma. Factors that contribute to the development of esophagitis include the caustic nature of the refluxate, the inability to clear the refluxate from the esophagus, the volume of gastric contents, and local mucosal protective functions. Some patients, particularly infants, may aspirate the reflux material.

Symptoms and Signs

The most prominent symptom of GERD is heartburn, with or without regurgitation of gastric contents into the mouth. Infants present with vomiting, irritability, anorexia, and sometimes symptoms of chronic aspiration. Both adults and infants with chronic aspiration may have cough, hoarseness, or wheezing.

Esophagitis may cause odynophagia and even esophageal hemorrhage, which is usually occult but can be massive. Peptic strictures cause a gradually progressive dysphagia for solid foods. Peptic esophageal ulcers cause the same type of pain as gastric or duodenal ulcers, but the pain is usually localized to the xiphoid or high substernal region. Peptic esophageal ulcers heal slowly, tend to recur, and usually leave a stricture on healing.


  • Clinical diagnosis

  • Endoscopy for patients not responding to empiric treatment

  • 24-hour pH testing for patients with typical symptoms but normal endoscopy

(See also the American College of Gastroenterology’s updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease.)

A detailed history points to the diagnosis. Patients with typical symptoms of GERD may be given a trial of acid-suppressing therapy. Patients who do not improve, or have long-standing symptoms or symptoms of complications, should undergo further testing.

Endoscopy, with cytologic washings and/or biopsy of abnormal areas, is the test of choice. Endoscopic biopsy is the only test that consistently detects the columnar mucosal changes of Barrett esophagus. Patients with unremarkable endoscopy findings who have typical symptoms despite treatment with proton pump inhibitors should undergo 24-hour pH testing. Although barium swallow readily shows esophageal ulcers and peptic strictures, it is less useful for mild to moderate reflux; in addition, most patients with abnormalities require subsequent endoscopy.

Esophageal manometry is used to evaluate esophageal peristalsis before surgical treatment.


  • Head of bed elevated

  • Coffee, alcohol, fats, and smoking avoided

  • Proton pump inhibitors, H2 blockers

Management of uncomplicated GERD consists of elevating the head of the bed about 15 cm (6 in) and avoiding the following:

  • Eating within 3 hours of bedtime

  • Strong stimulants of acid secretion (eg, coffee, alcohol)

  • Certain drugs (eg, anticholinergics)

  • Specific foods (eg, fats, chocolate)

  • Smoking

Weight loss is recommended for overweight patients and those who have gained weight recently.

Drug therapy is often with a proton pump inhibitor; all appear equally effective. For example, adults can be given omeprazole 20 mg, lansoprazole 30 mg, pantoprazole 40 mg, or esomeprazole 40 mg 30 minutes before breakfast. In some cases (eg, only partial response to once a day dosing), proton pump inhibitors may be given twice daily. Infants and children may be given these drugs at an appropriate lower single daily dose (ie, omeprazole 20 mg in children > 3 years, 10 mg in children < 3 years; lansoprazole 15 mg in children 30 kg, 30 mg in children > 30 kg). These drugs may be continued long-term, but the dose should be adjusted to the minimum required to prevent symptoms, including intermittent or as-needed dosing. H2 blockers or promotility agents (eg, metoclopramide 10 mg orally 30 minutes before meals and at bedtime) are less effective but may be added to a proton pump inhibitor regimen.

Antireflux surgery (usually fundoplication via laparoscopy) is done in patients with serious esophagitis, large hiatal hernias, hemorrhage, stricture, or ulcers. Esophageal strictures are managed by repeated endoscopic dilation.

Barrett esophagus may or may not regress with medical or surgical therapy. (See also the American College of Gastroenterology’s updated guidelines for the diagnosis, surveillance, and therapy of Barrett’s esophagus.) Because Barrett esophagus is a precursor to adenocarcinoma, endoscopic surveillance for malignant transformation is recommended every 3 to 5 years in nondysplastic disease. The American College of Gastroenterology's 2015 guidelines recommend endoscopic ablative therapy for patients with confirmed low-grade dysplasia and without life-limiting comorbidity; however, endoscopic surveillance every 12 months is an acceptable alternative. Patients with Barrett esophagus and confirmed high-grade dysplasia should be managed with endoscopic ablative therapy unless they have life-limiting comorbidity. Endoscopic ablative techniques for Barrett esophagus include mucosal resection, photodynamic therapy, cryotherapy, and laser ablation.

Key Points

  • Lower esophageal sphincter incompetence and transient relaxations allow gastric contents to reflux into the esophagus and sometimes into the larynx or lungs.

  • Complications include esophagitis, peptic esophageal ulcer, esophageal stricture, Barrett esophagus, and esophageal adenocarcinoma.

  • The main symptom in adults is heartburn, and infants present with vomiting, irritability, anorexia, and sometimes symptoms of chronic aspiration; at any age, chronic aspiration may cause cough, hoarseness, or wheezing.

  • Diagnose clinically; do endoscopy in patients not responding to empiric treatment and 24-hour pH monitoring if endoscopy is normal in patients with typical symptoms.

  • Treat with lifestyle changes (eg, head of bed elevation, weight loss, dietary trigger avoidance) and acid-suppressing therapy.

  • Antireflux surgery can help patients with complications or a large amount of symptomatic nonacid reflux.

More Information

Drugs Mentioned In This Article

Drug Name Select Trade
Click here for Patient Education
NOTE: This is the Professional Version. CONSUMERS: Click here for the Consumer Version
Professionals also read

Also of Interest


View All
How to Insert a Nasogastric Tube
How to Insert a Nasogastric Tube
3D Models
View All
Ileal Pouch–Anal Anastomosis (IPAA)
3D Model
Ileal Pouch–Anal Anastomosis (IPAA)